Table 7.
Examples of nanogel as a nanostructure for oral insulin delivery nanosystems.
| Materials | Method | Active Components | EE%; LE% |
Size (nm); PDI |
Zeta-Potential (mV) | In Vitro Release Study | Dose (IU kg−1) |
In Vivo Studies | References |
|---|---|---|---|---|---|---|---|---|---|
| (CMS-g-AA), iBAA | Aqueous dispersion copolymerization | Acrylic acid, carboxymethyl starch | - | pH 1.2, 480; pH 6.8, 700 |
- | pH 1.2, 4 h, 25%; pH 6.8, 4 h, 75% |
60 | rPA, 5.7% |
[41] |
| PLG, dextran | Covalent cross-linking | PBA, PEG | 44; - |
43.7; - |
−40 | pH7.4, 72 h, 40.2% (Cg: 1 mg mL−1), 72.8% (Cg: 3 mg mL−1), 81.5% |
- | - | [133] |
| EGDMA | - | VPBA, folic acid |
68; - |
166; - |
- | pH 1.2, 0–2 h, 10%; pH 6.8, 2–8 h, 50%; pH 7.4, 0–24 h, 90% (Cg: 15 mM) |
75 | BLG, 5 h, 42.9%; |
[134] |
CMS-g-AA: acrylate-grafted-carboxymethyl starch; iBAA: 2-isobutyl-acrylic acid; PLG: poly (L-glutamic acid); Cg: the concentration of glucose; EGDMA: ethylene glycol dimethacrylate; VPBA: 4-vinylbenzeneboronic acid.